Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Winthrop University Hospital.
Recruitment status was Active, not recruiting
Information provided by:
Winthrop University Hospital
First received: July 31, 2009
Last updated: May 7, 2010
Last verified: May 2010
The study is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. The investigators' study focused on comparing different treatment arms with regard to their neopterin levels and correlating neopterin levels to the Thrombolysis in Myocardial Infarction (TIMI) risk score. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay.
||Observational Model: Cohort
Time Perspective: Prospective
||Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin
Primary Outcome Measures:
- Determine if serum neopterin is a useful marker in risk stratifying patients with acute coronary syndromes as it relates to vascular endothelial dysfunction. [ Time Frame: 8 year study - 2011 anticipated study completion ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Evaluate whether serum neopterin is a useful marker in a similar manner as LPGD-S. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||September 2011 (Final data collection date for primary outcome measure)
Patients diagnosed with acute coronary syndrome (ACS)
|Ages Eligible for Study:
||19 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Chest pain and either ST segment elevation or depression > 0.1 mV in at least 2 contiguous electrocardiographic leads as well as elevation in troponin levels.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00952055
|Mineola, New York, United States, 11501 |
Winthrop University Hospital
||Joshua DeLeon, MD
||Winthrop University Hospital
No publications provided
||Joshua DeLeon, M.D. Principal Investigator, Winthrop-University Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||July 31, 2009
||May 7, 2010
||United States: Institutional Review Board
Keywords provided by Winthrop University Hospital:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 31, 2014
Acute Coronary Syndrome
Signs and Symptoms